Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T17:24:37.298Z Has data issue: false hasContentIssue false

Introduction

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer  and
Stephen M. Stahl
Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

The year 2018 marked the 60th anniversary of clozapine’s synthesis, and the 30th anniversary of the September 1988 Archives of General Psychiatry paper by Kane and colleagues documenting clozapine’s superior efficacy in treatment-resistant schizophrenia. The peer view literature since 1988 demonstrates ongoing interest in clozapine, with 350–450 papers per year listed in PubMed (see Figure 1). The ensuing decades have also seen other evidence-based uses for clozapine (e.g. schizophrenia patients with suicidality or aggression, Parkinson’s disease psychosis, treatment-resistant mania), but treatment-resistant schizophrenia spectrum disorders remain the most common indication. Lamentably, clozapine remains significantly underutilized for treatment-resistant schizophrenia despite compelling evidence of efficacy in this population, and the enormous individual and societal benefits that can accrue from effective management of treatment-resistant patients.

Type
Chapter
Information
The Clozapine Handbook
Stahl's Handbooks
 , pp. 1 - 9
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle ScholarPubMed
Kelly, D. L., Freudenreich, O., Sayer, M. A., et al. (2018). Addressing barriers to clozapine underutilization: a national effort. Psychiatric Services, 69, 224–227.CrossRefGoogle ScholarPubMed
Charlson, F. J., Ferrari, A. J., Santomauro, D. F., et al. (2018). Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44, 1195–1203.Google Scholar
Vos, T., Abajobir, A. A., Abbafati, C., et al. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211–1259.CrossRefGoogle Scholar
Cloutier, M., Aigbogun, M. S., Guerin, A., et al. (2016). The economic burden of schizophrenia in the United States in 2013. Journal of Clinical Psychiatry, 77, 764–771.CrossRefGoogle ScholarPubMed
Kennedy, J. L., Altar, C. A., Taylor, D. L., et al. (2014). The social and economic burden of treatment-resistant schizophrenia: A systematic literature review. International Clinical Psychopharmacology, 29, 63–76.Google Scholar
Howes, O. D., McCutcheon, R., Agid, O., et al. (2017). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry, 174, 216–229.CrossRefGoogle Scholar
Stroup, T. S., Gerhard, T., Crystal, S., et al. (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services, 65, 186–192.CrossRefGoogle ScholarPubMed
Downs, J. and Zinkler, M. (2007). Clozapine: National review of postcode prescribing. Psychiatric Bulletin, 31, 384–387.Google Scholar
Sultan, R. S., Olfson, M., Correll, C. U., et al. (2017). Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. Journal of Clinical Psychiatry, 78, e933–e939.CrossRefGoogle ScholarPubMed
Cohen, D. (2014). Prescribers fear as a major side-effect of clozapine. Acta Psychiatrica Scandinavica, 130, 154–155.Google Scholar
Nielsen, J., Dahm, M., Lublin, H., et al. (2010). Psychiatrists’ attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology, 24, 965–971.CrossRefGoogle ScholarPubMed
Grover, S., Balachander, S., Chakarabarti, S., et al. (2015). Prescription practices and attitude of psychiatrists towards clozapine: A survey of psychiatrists from India. Asian Journal of Psychiatry, 18, 57–65.CrossRefGoogle ScholarPubMed
Tungaraza, T. E. and Farooq, S. (2015). Clozapine prescribing in the UK: Views and experience of consultant psychiatrists. Therapeutic Advances in Psychopharmacology, 5, 88–96.CrossRefGoogle ScholarPubMed
Carruthers, J., Radigan, M., Erlich, M. D., et al. (2016). An initiative to improve clozapine prescribing in New York State. Psychiatric Services, 67(4), 369–371.CrossRefGoogle ScholarPubMed
Olfson, M., Gerhard, T., Crystal, S., et al. (2016). Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatric Services, 67, 152.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Introduction
  • Jonathan M. Meyer, University of California, San Diego, Stephen M. Stahl, University of California, San Diego
  • Book: The Clozapine Handbook
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108553575.002
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Introduction
  • Jonathan M. Meyer, University of California, San Diego, Stephen M. Stahl, University of California, San Diego
  • Book: The Clozapine Handbook
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108553575.002
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Introduction
  • Jonathan M. Meyer, University of California, San Diego, Stephen M. Stahl, University of California, San Diego
  • Book: The Clozapine Handbook
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108553575.002
Available formats
×